Biotechnology for Healthy Ageing

Expected Impact:This Challenge looks to accelerate the development and uptake of clinically validated interventions that target the root cause of multiple age-related morbidities. It will: Deliver biotechnology-based interventions for healthy ageing Accelerate the implementation of personalised care in ageing based on molecular phenotyping​Provide recommendations for regulatory pathways addressing ageing as a target to inform developers, regulators, and other decision makers​, and Improve citizen literacy on longevity. Expected Outcome:Ambitious proposals put forward under this call will deliver:Proof-of-concepts (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an intervention Tools to facilitate development or adoption of the interventions above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models​, and Approaches to address the shared regulatory hurdles and societal challenges linked to ageing-related interventions, thereby facilitating their adoption​. Portfolio approachThe portfolio of projects selected under this Challenge will ensure a coverage of projects developing interventions, biomarkers and NAMs, considering the following guidelines for portfolio composition: Interventions: no more than 5 projects. The portfolio of selected projects should collectively address a variety molecular and cellular processes related to ageing, and a variety of different age-related diseases. Biomarkers: no more than 3 projects. Projects will be selected to capture different application areas (diagnostic, predictive, prognostic biomarker), with preference to the inclusion of at least one diagnostic biomarker). NAMs: No more than 2 projects. Projects will be selected to capture a diversity of approaches to assess a